Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous vs Sequential Ingenol Mebutate for Actinic Keratosis
NCT01787383Phase 3Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2013
- Primary completion
- Jan 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ingenol mebutate in actinic keratosis (AK) (2 arms), sponsored by LEO Pharma. Primary endpoint: Composite Local Skin Reaction Score. Started Feb 2013; status: completed.
02
Drugs
ingenol mebutate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01787383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787383.